VA
VR Adviser’s KalVista Pharmaceuticals KALV Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $76.1M | Buy |
6,728,985
+25,000
| +0.4% | +$283K | 5.7% | 5 |
|
|
2025
Q1 | $77.4M | Buy |
6,703,985
+454,254
| +7% | +$5.24M | 6.58% | 5 |
|
|
2024
Q4 | $52.9M | Hold |
6,249,731
| – | – | 3.63% | 9 |
|
|
2024
Q3 | $72.4M | Hold |
6,249,731
| – | – | 3.79% | 9 |
|
|
2024
Q2 | $73.6M | Hold |
6,249,731
| – | – | 4.69% | 7 |
|
|
2024
Q1 | $74.1M | Buy |
6,249,731
+2,157,000
| +53% | +$25.6M | 3.53% | 7 |
|
|
2023
Q4 | $50.1M | Buy |
4,092,731
+1,176,064
| +40% | +$14.4M | 3.44% | 9 |
|
|
2023
Q3 | $28.1M | Hold |
2,916,667
| – | – | 2.96% | 11 |
|
|
2023
Q2 | $26.3M | Hold |
2,916,667
| – | – | 4.2% | 8 |
|
|
2023
Q1 | $22.9M | Hold |
2,916,667
| – | – | 4.48% | 9 |
|
|
2022
Q4 | $19.7M | Buy |
+2,916,667
| New | +$19.7M | 3.32% | 11 |
|